Related Experiment Video

Updated: Aug 17, 2026

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

Cyclo-oxygenase 2 inhibitor, nabumetone, inhibits proliferation in chronic myeloid leukemia cell lines

Filiz Vural1, Mehmet Ali Ozcan, Güner Hayri Ozsan

  • 1Department of Internal Medicine, Division of Hematology-Oncology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.

Leukemia & Lymphoma
|July 16, 2005
PubMed

Insights

Nabumetone (NBT), a COX2 inhibitor, inhibits proliferation in chronic myeloid leukemia cell lines. NBT also enhances adriamycin

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cyclo-oxygenase (COX) inhibitors, particularly COX2 inhibitors, show anti-tumor effects with fewer side effects.
  • Limited data exists on COX2 inhibitors in hematological malignancies.
  • Nabumetone (NBT) is a potent COX2 inhibitor.

Purpose of the Study:

  • To investigate the anti-proliferative and apoptotic effects of nabumetone (NBT) in chronic myeloid leukemia (CML) cell lines.
  • To evaluate NBT as a single agent and in combination with adriamycin (ADR) and interferon alpha (IFN-a).

Main Methods:

  • Utilized K-562 and Meg-01 CML blastic cell lines.
  • Assessed NBT's effects alone and in combination with ADR and IFN-a.
  • Measured proliferation inhibition, apoptosis induction, and Bcl-2 expression.

Main Results:

  • NBT demonstrated dose-dependent inhibition of proliferation in both cell lines.
  • NBT alone did not induce significant apoptosis but potentiated ADR's apoptotic effect in K-562 cells.
  • NBT reduced Bcl-2 expression (11% vs. 2%) and showed no significant synergistic effect with IFN-a.

Conclusions:

  • Nabumetone inhibits proliferation in CML cell lines.
  • NBT potentiates the apoptotic effect of adriamycin in K-562 cells.
  • NBT shows potential in managing CML, particularly in combination with ADR.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...